STOCK TITAN

Lynwood discloses 5.4% Kazia Therapeutics (KZIA) stake via ADS

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Lynwood Opportunities Master Fund and its affiliates have disclosed a sizable passive stake in Kazia Therapeutics Limited. The fund, together with its investment manager Lynwood Capital Management Inc. and principal Ben Shapiro, reports beneficial ownership of 307,998,500 Ordinary Shares, representing 5.4% of Kazia’s Ordinary Shares as of the close of business on January 15, 2026. This percentage is based on 5,667,995,734 Ordinary Shares outstanding as of December 11, 2025.

The position is held through Kazia’s American Depositary Shares, each representing 500 Ordinary Shares, under CUSIP 48669G303. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Kazia, indicating a passive investment stance.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Kazia Therapeutics shares do the filers report owning?

The Reporting Persons disclose beneficial ownership of 307,998,500 Ordinary Shares of Kazia Therapeutics Limited.

What percentage of Kazia Therapeutics’ equity does this holding represent?

The reported 307,998,500 Ordinary Shares represent 5.4% of the outstanding Ordinary Shares, based on 5,667,995,734 shares outstanding as of December 11, 2025.

How are the Kazia Therapeutics shares held by Lynwood structured?

The Reporting Persons hold their position through American Depositary Shares (ADS), with each ADS representing 500 Ordinary Shares. The ADS have CUSIP 48669G303.

Does Lynwood seek to influence control of Kazia Therapeutics?

The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Kazia and are not part of any control-related transaction, other than activities solely in connection with a nomination under Rule 240.14a-11.

As of what date is the ownership information for Kazia Therapeutics effective?

The beneficial ownership information is given as of the close of business on January 15, 2026, with outstanding shares based on Kazia data as of December 11, 2025.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Lynwood Capital Management Inc.
Signature:/s/ Ben Shapiro
Name/Title:Ben Shapiro / Authorized Signatory
Date:01/23/2026
Ben Shapiro
Signature:/s/ Ben Shapiro
Name/Title:N/A
Date:01/23/2026
Lynwood Opportunities Master Fund
Signature:/s/ Ben Shapiro
Name/Title:Ben Shapiro / Authorized Signatory
Date:01/23/2026
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement